Empagliflozin for diabetes; Pneumococcal vaccines; PCSK9 antibodies

This episode features Dr. David Nathan, discussing the diabetes drug, empagliflozin, and its impact on diabetes and cardiovascular outcomes (01:07); Dr. John Bartlett, discussing revisions to US recommendations for pneumococcal vaccination in older adults (09:30); and Dr. Mason Freeman, discussing use of the newly approved PCSK9 antibodies in the treatment of hyperlipidemia (17:53). Dr. Nancy Sokol hosts.

Podcast References

1. Segment on empagliflozin (Dr. Nathan):

Zinman, B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117.

2. Segment on pneumococcal vaccination (Dr. Bartlett):

Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015; 64:944.

3. Segment on PCSK9 antibodies (Dr. Freeman):

Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1488.

Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500.